CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.

Mayr, Lisa; Pirker, Christine; Lötsch, Daniela; Van Schoonhoven, Sushilla; Windhager, Reinhard; Englinger, Bernhard; Berger, Walter; Kubista, Bernd

Mayr, Lisa; Pirker, Christine; Lötsch, Daniela; Van Schoonhoven, Sushilla; Windhager, Reinhard; Englinger, Bernhard; Berger, Walter; Kubista, Bernd.

Afiliación

Mayr L; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Pirker C; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Lötsch D; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Van Schoonhoven S; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Windhager R; Department of Orthopaedics, Medical University Vienna, 1090 Vienna, Austria.
Englinger B; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Berger W; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.
Kubista B; Department of Orthopaedics, Medical University Vienna, 1090 Vienna, Austria.

Oncotarget ; 8(69): 114095-114108, 2017 Dec 26.

Article en En | MEDLINE | ID: mdl-29371972

Palabras clave

CD44; cilengitide; metastasis; metastatic model; osteosarcoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Austria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google